Trial
NCT03604991
Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
Phase IISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Intervention
Biospecimen Collection
Why stopped
End of Initial Phase of Multi-phase protocol
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-02